Pharmacovigilance challenges in Biosimilars


This session of the Biosimilars 2022 will investigate the future and FDA activities that have just been declared to incorporate upgraded following and follow-up of post promoting observation issues, arranged enhancements in AERS, and pilots of new post market drug-monitoring strategies and ADR related issues. Biosimilar rules for pharmacovigilance practice and pharmacoepidemiology are the focuses that will be laid emphasis in this session. U.S. normal yearly spending development from 2002 to 2007 was 16% for biologics, contrasted and 3.7% for drugs. In same extent pharmacovigilance for biosimilar has been nearly more than other pharmaceutical items.

Current issues in biosimilars pharmacovigilance

  1. Unfriendly medication responses with biologics and biosimilar items
  2. Recognition and assessment of medication security signals
  3. Job of pharma businesses in the improvement of pharmacovigilance framework
  4. Great pharmacovigilance practice and pharmacoepidemiology

    Related Conference of Pharmacovigilance challenges in Biosimilars

    July 27-28, 2026

    19th World Drug Delivery Summit

    Paris, France
    July 27-28, 2026

    39th World Congress on Pharmacology

    Rome, Italy
    September 14-15, 2026

    6th International Conference on Pharmaceutical Chemistry

    Paris, France
    September 24-25, 2026

    6th World Congress on Rare Diseases & Orphan Drugs

    Paris, France
    November 26-27, 2026

    5th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 26-27, 2026

    5th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland

    Pharmacovigilance challenges in Biosimilars Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in